Novel and Emerging Drugs for Acute Myeloid Leukemia

Author(s): E. M. Stein, M. S. Tallman.

Journal Name: Current Cancer Drug Targets

Volume 12 , Issue 5 , 2012

Submit Manuscript
Submit Proposal

Abstract:

Acute myeloid leukemia (AML) is a challenging disease to treat with the majority of patients dying from their illness. While overall survival has been markedly prolonged in acute promyelocytic leukemia (APL), survival in younger adults with other subtypes of AML has only modestly improved over the last twenty years. Physicians who treat AML eagerly await drugs like Imatinib for chronic myeloid leukemia, Cladribine for hairy cell leukemia, and Rituximab for non-Hodgkin Lymphoma which have had an important impact on improving outcome. Recent research efforts have focused on refining traditional chemotherapeutic agents to make them more active in AML, targeting specific genetic mutations in myeloid leukemia cells, and utilizing novel agents such as Lenalidomide that have shown activity in other hematologic malignancies. Here, we focus on reviewing the recent literature on agents that may assume a role in clinical practice for patients with AML over the next five years.

Keywords: Acute Myeloid Leukemia, novel drugs, emerging agents

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 5
Year: 2012
Page: [522 - 530]
Pages: 9
DOI: 10.2174/156800912800673248
Price: $58

Article Metrics

PDF: 8